US 12,343,350 B2
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
Giuseppe Bianchi, Milan (IT); Patrizia Ferrari, Varese (IT); Mara Ferrandi, Milan (IT); and Paolo Barassi, Castelveccana (IT)
Assigned to Windtree Therapeutics, Inc., Warrington, PA (US)
Filed by Windtree Therapeutics, Inc., Warrington, PA (US)
Filed on Jan. 6, 2023, as Appl. No. 18/150,870.
Application 18/150,870 is a continuation of application No. 17/517,530, filed on Nov. 2, 2021, granted, now 11,583,540.
Application 17/517,530 is a continuation of application No. 17/233,302, filed on Apr. 16, 2021, granted, now 11,197,869, issued on Dec. 14, 2021.
Application 17/233,302 is a continuation of application No. PCT/US2019/060961, filed on Nov. 12, 2019.
Claims priority of provisional application 62/814,149, filed on Mar. 5, 2019.
Prior Publication US 2023/0293548 A1, Sep. 21, 2023
Int. Cl. A61K 31/5685 (2006.01); A61K 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/06 (2006.01)
CPC A61K 31/5685 (2013.01) [A61K 9/009 (2013.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01)] 19 Claims
 
1. A compound having a formula (III)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, ester, solvate, hydrate, or polymorph thereof.